Acute Hemodynamic Effects of Intravenous Ibutilide in Patients With or Without Reduced Left Ventricular Function
| Autor: | Kim T. Perry, Bruce S. Stambler, Alan H. Kadish, Karen J. Beckman, Kenneth A. Ellenbogen, James T. VanderLugt, John Camm |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Adult
Male medicine.medical_specialty medicine.medical_treatment Ibutilide Hemodynamics Blood Pressure Torsades de pointes Antiarrhythmic agent QT interval Ventricular Dysfunction Left Heart Rate Internal medicine medicine Humans Cardiac Output Infusions Intravenous Aged Proarrhythmia Sulfonamides Ejection fraction Dose-Response Relationship Drug business.industry Atrial fibrillation Middle Aged medicine.disease Treatment Outcome Anesthesia Cardiology Female Cardiology and Cardiovascular Medicine business Anti-Arrhythmia Agents medicine.drug |
| Zdroj: | The American Journal of Cardiology. 80:458-463 |
| ISSN: | 0002-9149 |
| DOI: | 10.1016/s0002-9149(97)00395-0 |
| Popis: | Many antiarrhythmic agents have adverse hemodynamic effects which limit their use in patients with impaired ventricular function or during tachyarrhythmias. Ibutilide is an intravenous, selective class III antiarrhythmic agent that is effective for conversion of atrial fibrillation or flutter. This multicenter, randomized, placebo-controlled, dose-ranging study evaluated the effects of intravenous ibutilide on hemodynamic parameters during invasive monitoring in 47 patients with or without reduced left ventricular ejection fraction (LVEF) > 35% or < or = 35%. Patients received either placebo or ibutilide as a 10-minute loading and a 30-minute maintenance infusion using 1 of the following dosing regimens: placebo then placebo (n = 12); 0.01 then 0.002 mg/kg (n = 12); 0.02 then 0.004 mg/kg (n = 12); or 0.03 then 0.006 mg/kg (n = 11). Ibutilide significantly increased QT and QTc intervals in a dose-related manner with mean increases ranging from 51 to 99 ms, but did not alter the PR interval or QRS duration. During ibutilide infusion, a few small but statistically significant changes from baseline in several hemodynamic variables were present. However, the changes in cardiac output, pulmonary artery or capillary wedge pressures, blood pressure, or heart rate in patients receiving ibutilide were not significantly different from the changes in patients receiving placebo. Thus, ibutilide did not cause clinically important adverse hemodynamic effects, even in patients with depressed ventricular function. One patient developed 2 episodes of nonsustained torsades de pointes during ibutilide. These results demonstrate that with careful monitoring for proarrhythmia, ibutilide can be used safely from a hemodynamic standpoint in the acute treatment of arrhythmias, even in patients with reduced ventricular function. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect